Scott Dreyer
Corporate Officer/Principal presso COLLEGIUM PHARMACEUTICAL, INC.
Patrimonio netto: 5 M $ in data 31/03/2024
Profilo
Scott Dreyer is currently the Chief Commercial Officer & Executive VP at Collegium Pharmaceutical, Inc. He previously worked as the Vice President-US Hospital & Oncology Sales at Merck & Co., Inc. from 1994 to 2013.
From 2014 to 2016, he served as the Chief Marketing Officer at Biogen, Inc. He then worked as the Senior VP-Marketing & Commercial Operations at The Medicines Co. from 2016 to 2017.
Mr. Dreyer completed his undergraduate degree at the University of Messiah in 1994.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 26/02/2024 | 138 918 ( 0.43% ) | 5 M $ | 31/03/2024 |
Posizioni attive di Scott Dreyer
| Società | Posizione | Inizio |
|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Corporate Officer/Principal | 10/07/2018 |
Precedenti posizioni note di Scott Dreyer
| Società | Posizione | Fine |
|---|---|---|
| THE MEDICINES COMPANY | Sales & Marketing | 01/12/2017 |
| BIOGEN INC. | Sales & Marketing | 01/09/2016 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2013 |
Formazione di Scott Dreyer
| University of Messiah | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| COLLEGIUM PHARMACEUTICAL, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
- Borsa valori
- Insiders
- Scott Dreyer
